(ABBV) AbbVie - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US00287Y1091
Stock:
Total Rating 55
Risk 80
Buy Signal 0.20
| Risk 5d forecast | |
|---|---|
| Volatility | 26.5% |
| Relative Tail Risk | -11.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.58 |
| Alpha | 12.05 |
| Character TTM | |
|---|---|
| Beta | 0.212 |
| Beta Downside | 0.709 |
| Drawdowns 3y | |
|---|---|
| Max DD | 20.74% |
| CAGR/Max DD | 0.89 |
EPS (Earnings per Share)
Revenue
Primary Risks
P/E ratio: 95.0636
Description: ABBV AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. AbbVie Inc. has strategic partnership with OSE Immunotherapeutics. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 4.23b TTM > 0 and > 6% of Revenue |
| FCF/TA: 2.53 > 0.02 and ΔFCF/TA 239.9 > 1.0 |
| NWC/Revenue: -55.86% < 20% (prev -23.37%; Δ -32.48% < -1%) |
| CFO/TA 2.53 > 3% & CFO 13.81b > Net Income 4.23b |
| Net Debt (-5.23b) to EBITDA (28.29b): -0.18 < 3 |
| Current Ratio: 0.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.77b) vs 12m ago 0.06% < -2% |
| Gross Margin: 73.34% > 18% (prev 0.70%; Δ 7264 % > 0.5%) |
| Asset Turnover: 86.99% > 50% (prev 41.68%; Δ 45.31% > 0%) |
| Interest Coverage Ratio: 3.33 > 6 (EBITDA TTM 28.29b / Interest Expense TTM 2.83b) |
Altman Z'' -15.00
| A: -6.26 (Total Current Assets 5.23b - Total Current Liabilities 39.39b) / Total Assets 5.46b |
| B: -2.61 (Retained Earnings -14.23b / Total Assets 5.46b) |
| C: 0.13 (EBIT TTM 9.43b / Avg Total Assets 70.31b) |
| D: -0.10 (Book Value of Equity -2.64b / Total Liabilities 26.29b) |
| Altman-Z'' Score: -48.77 = D |
Beneish M
| DSRI: none (Receivables none/10.92b, Revenue 61.16b/56.33b) |
| GMI: 0.95 (GM 73.34% / 69.99%) |
| AQI: none (AQ_t none / AQ_t-1 none) |
| SGI: 1.09 (Revenue 61.16b / 56.33b) |
| TATA: -1.76 (NI 4.23b - CFO 13.81b) / TA 5.46b) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of ABBV shares?
As of February 24, 2026, the stock is trading at USD 229.48 with a total of 5,459,916 shares traded.
Over the past week, the price has changed by -1.45%, over one month by +4.66%, over three months by +0.79% and over the past year by +16.22%.
Over the past week, the price has changed by -1.45%, over one month by +4.66%, over three months by +0.79% and over the past year by +16.22%.
Is ABBV a buy, sell or hold?
AbbVie has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy ABBV.
- StrongBuy: 12
- Buy: 4
- Hold: 12
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ABBV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 248.3 | 8.2% |
| Analysts Target Price | 248.3 | 8.2% |
ABBV Fundamental Data Overview February 21, 2026
P/E Trailing = 95.0636
P/E Forward = 16.0256
P/S = 6.4832
P/B = 50.4573
P/EG = 0.3879
Revenue TTM = 61.16b USD
EBIT TTM = 9.43b USD
EBITDA TTM = 28.29b USD
Long Term Debt = 62.97b USD (from longTermDebt, two quarters ago)
Short Term Debt = 5.77b USD (from shortTermDebt, two quarters ago)
Debt = 68.74b USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = -5.23b USD (from netDebt column, last quarter)
Enterprise Value = 460.03b USD (396.51b + Debt 68.74b - CCE 5.23b)
Interest Coverage Ratio = 3.33 (Ebit TTM 9.43b / Interest Expense TTM 2.83b)
EV/FCF = 33.31x (Enterprise Value 460.03b / FCF TTM 13.81b)
FCF Yield = 3.00% (FCF TTM 13.81b / Enterprise Value 460.03b)
FCF Margin = 22.58% (FCF TTM 13.81b / Revenue TTM 61.16b)
Net Margin = 6.91% (Net Income TTM 4.23b / Revenue TTM 61.16b)
Gross Margin = 73.34% ((Revenue TTM 61.16b - Cost of Revenue TTM 16.31b) / Revenue TTM)
Gross Margin QoQ = 84.02% (prev 66.38%)
Tobins Q-Ratio = 84.30 (set to none) (Enterprise Value 460.03b / Total Assets 5.46b)
Interest Expense / Debt = 0.95% (Interest Expense 655.0m / Debt 68.74b)
Taxrate = 31.97% (853.0m / 2.67b)
NOPAT = 6.42b (EBIT 9.43b * (1 - 31.97%))
Current Ratio = 0.13 (Total Current Assets 5.23b / Total Current Liabilities 39.39b)
Debt / Equity = -26.45 (negative equity) (Debt 68.74b / totalStockholderEquity, last quarter -2.60b)
Debt / EBITDA = -0.18 (Net Debt -5.23b / EBITDA 28.29b)
Debt / FCF = -0.38 (Net Debt -5.23b / FCF TTM 13.81b)
Total Stockholder Equity = -1.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.01% (Net Income 4.23b / Total Assets 5.46b)
RoE = -422.2% (negative equity) (Net Income TTM 4.23b / Total Stockholder Equity -1.00b)
RoCE = 15.22% (EBIT 9.43b / Capital Employed (Equity -1.00b + L.T.Debt 62.97b))
RoIC = 9.27% (NOPAT 6.42b / Invested Capital 69.24b)
WACC = 5.81% (E(396.51b)/V(465.26b) * Re(6.70%) + D(68.74b)/V(465.26b) * Rd(0.95%) * (1-Tc(0.32)))
Discount Rate = 6.70% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.06%
[DCF Debug] Terminal Value 86.20% ; FCFF base≈15.42b ; Y1≈15.21b ; Y5≈15.68b
Fair Price DCF = 268.0 (EV 468.36b - Net Debt -5.23b = Equity 473.59b / Shares 1.77b; r=5.90% [WACC]; 5y FCF grow -2.17% → 2.90% )
EPS Correlation: -63.83 | EPS CAGR: -4.65% | SUE: -1.23 | # QB: 0
Revenue Correlation: 42.75 | Revenue CAGR: 5.62% | SUE: 0.45 | # QB: 0
EPS next Quarter (2026-03-31): EPS=3.01 | Chg30d=-0.108 | Revisions Net=-4 | Analysts=19
EPS current Year (2026-12-31): EPS=14.53 | Chg30d=+0.304 | Revisions Net=+9 | Growth EPS=+45.3% | Growth Revenue=+9.7%
EPS next Year (2027-12-31): EPS=16.07 | Chg30d=+0.130 | Revisions Net=-1 | Growth EPS=+10.6% | Growth Revenue=+8.0%
P/E Forward = 16.0256
P/S = 6.4832
P/B = 50.4573
P/EG = 0.3879
Revenue TTM = 61.16b USD
EBIT TTM = 9.43b USD
EBITDA TTM = 28.29b USD
Long Term Debt = 62.97b USD (from longTermDebt, two quarters ago)
Short Term Debt = 5.77b USD (from shortTermDebt, two quarters ago)
Debt = 68.74b USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = -5.23b USD (from netDebt column, last quarter)
Enterprise Value = 460.03b USD (396.51b + Debt 68.74b - CCE 5.23b)
Interest Coverage Ratio = 3.33 (Ebit TTM 9.43b / Interest Expense TTM 2.83b)
EV/FCF = 33.31x (Enterprise Value 460.03b / FCF TTM 13.81b)
FCF Yield = 3.00% (FCF TTM 13.81b / Enterprise Value 460.03b)
FCF Margin = 22.58% (FCF TTM 13.81b / Revenue TTM 61.16b)
Net Margin = 6.91% (Net Income TTM 4.23b / Revenue TTM 61.16b)
Gross Margin = 73.34% ((Revenue TTM 61.16b - Cost of Revenue TTM 16.31b) / Revenue TTM)
Gross Margin QoQ = 84.02% (prev 66.38%)
Tobins Q-Ratio = 84.30 (set to none) (Enterprise Value 460.03b / Total Assets 5.46b)
Interest Expense / Debt = 0.95% (Interest Expense 655.0m / Debt 68.74b)
Taxrate = 31.97% (853.0m / 2.67b)
NOPAT = 6.42b (EBIT 9.43b * (1 - 31.97%))
Current Ratio = 0.13 (Total Current Assets 5.23b / Total Current Liabilities 39.39b)
Debt / Equity = -26.45 (negative equity) (Debt 68.74b / totalStockholderEquity, last quarter -2.60b)
Debt / EBITDA = -0.18 (Net Debt -5.23b / EBITDA 28.29b)
Debt / FCF = -0.38 (Net Debt -5.23b / FCF TTM 13.81b)
Total Stockholder Equity = -1.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.01% (Net Income 4.23b / Total Assets 5.46b)
RoE = -422.2% (negative equity) (Net Income TTM 4.23b / Total Stockholder Equity -1.00b)
RoCE = 15.22% (EBIT 9.43b / Capital Employed (Equity -1.00b + L.T.Debt 62.97b))
RoIC = 9.27% (NOPAT 6.42b / Invested Capital 69.24b)
WACC = 5.81% (E(396.51b)/V(465.26b) * Re(6.70%) + D(68.74b)/V(465.26b) * Rd(0.95%) * (1-Tc(0.32)))
Discount Rate = 6.70% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.06%
[DCF Debug] Terminal Value 86.20% ; FCFF base≈15.42b ; Y1≈15.21b ; Y5≈15.68b
Fair Price DCF = 268.0 (EV 468.36b - Net Debt -5.23b = Equity 473.59b / Shares 1.77b; r=5.90% [WACC]; 5y FCF grow -2.17% → 2.90% )
EPS Correlation: -63.83 | EPS CAGR: -4.65% | SUE: -1.23 | # QB: 0
Revenue Correlation: 42.75 | Revenue CAGR: 5.62% | SUE: 0.45 | # QB: 0
EPS next Quarter (2026-03-31): EPS=3.01 | Chg30d=-0.108 | Revisions Net=-4 | Analysts=19
EPS current Year (2026-12-31): EPS=14.53 | Chg30d=+0.304 | Revisions Net=+9 | Growth EPS=+45.3% | Growth Revenue=+9.7%
EPS next Year (2027-12-31): EPS=16.07 | Chg30d=+0.130 | Revisions Net=-1 | Growth EPS=+10.6% | Growth Revenue=+8.0%